473 related articles for article (PubMed ID: 19166710)
1. Variability in responsiveness to oral antiplatelet therapy.
Angiolillo DJ
Am J Cardiol; 2009 Feb; 103(3 Suppl):27A-34A. PubMed ID: 19166710
[TBL] [Abstract][Full Text] [Related]
2. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
Collet JP; Montalescot G
Int J Cardiol; 2009 Mar; 133(1):8-17. PubMed ID: 19187982
[TBL] [Abstract][Full Text] [Related]
3. Dual antiplatelet drug resistance in patients with acute coronary syndrome.
Guha S; Sardar P; Guha P; Roy S; Mookerjee S; Chakrabarti P; Deb PK; Chaudhuri U; Deb S; Karmakar R; Dasgupta AK; Lahiri P
Indian Heart J; 2009; 61(1):68-73. PubMed ID: 19729693
[TBL] [Abstract][Full Text] [Related]
4. Current antiplatelet therapies: benefits and limitations.
Angiolillo DJ; Guzman LA; Bass TA
Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
[TBL] [Abstract][Full Text] [Related]
5. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
7. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Wiviott SD
Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
9. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
Robinson A; Das K; Koshy SK; Das P
Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA
Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929
[TBL] [Abstract][Full Text] [Related]
11. Facts and controversies of aspirin and clopidogrel therapy.
Faxon DP; Freedman JE
Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409
[TBL] [Abstract][Full Text] [Related]
12. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Bernlochner I; Byrne RA; Kastrati A; Sibbing D
Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
[TBL] [Abstract][Full Text] [Related]
13. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Bhatt DL
Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
Denardo SJ; Davis KE; Tcheng JE
Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
[TBL] [Abstract][Full Text] [Related]
15. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Spinler SA
Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
[TBL] [Abstract][Full Text] [Related]
18. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Rajagopal V; Bhatt DL
Semin Thromb Hemost; 2004 Dec; 30(6):649-55. PubMed ID: 15630671
[TBL] [Abstract][Full Text] [Related]
19. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Alfonso F; Macaya C; Bass TA; Costa MA
J Am Coll Cardiol; 2007 Apr; 49(14):1505-16. PubMed ID: 17418288
[TBL] [Abstract][Full Text] [Related]
20. Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST).
Dewilde W; Berg JT
Am Heart J; 2009 Nov; 158(5):713-8. PubMed ID: 19853687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]